Skip to main content

Research Repository

Advanced Search

Perlecan (HSPG2) promotes structural, contractile, and metabolic development of human cardiomyocytes

Johnson, Benjamin B; Cosson, Marie-Victoire; Tsansizi, Lorenza I; Holmes, Terri L; Gilmore, Tegan; Hampton, Katherine; Song, Ok-Ryul; Vo, Nguyen T N; Nasir, Aishah; Chabronova, Alzbeta; Denning, Chris; Peffers, Mandy J; Merry, Catherine L R; Whitelock, John; Troeberg, Linda; Rushworth, Stuart A; Bernardo, Andreia S; Smith, James G W

Perlecan (HSPG2) promotes structural, contractile, and metabolic development of human cardiomyocytes Thumbnail


Authors

Benjamin B Johnson

Marie-Victoire Cosson

Lorenza I Tsansizi

Terri L Holmes

Tegan Gilmore

Katherine Hampton

Ok-Ryul Song

Nguyen T N Vo

Alzbeta Chabronova

CHRIS DENNING chris.denning@nottingham.ac.uk
Professor of Stem Cell Biology

Mandy J Peffers

Catherine L R Merry

John Whitelock

Linda Troeberg

Stuart A Rushworth

Andreia S Bernardo

James G W Smith



Abstract

Perlecan (HSPG2), a heparan sulfate proteoglycan similar to agrin, is key for extracellular matrix (ECM) maturation and stabilization. Although crucial for cardiac development, its role remains elusive. We show that perlecan expression increases as cardiomyocytes mature in vivo and during human pluripotent stem cell differentiation to cardiomyocytes (hPSC-CMs). Perlecan-haploinsuffient hPSCs (HSPG2+/−) differentiate efficiently, but late-stage CMs have structural, contractile, metabolic, and ECM gene dysregulation. In keeping with this, late-stage HSPG2+/− hPSC-CMs have immature features, including reduced ⍺-actinin expression and increased glycolytic metabolism and proliferation. Moreover, perlecan-haploinsuffient engineered heart tissues have reduced tissue thickness and force generation. Conversely, hPSC-CMs grown on a perlecan-peptide substrate are enlarged and display increased nucleation, typical of hypertrophic growth. Together, perlecan appears to play the opposite role of agrin, promoting cellular maturation rather than hyperplasia and proliferation. Perlecan signaling is likely mediated via its binding to the dystroglycan complex. Targeting perlecan-dependent signaling may help reverse the phenotypic switch common to heart failure.

Citation

Johnson, B. B., Cosson, M.-V., Tsansizi, L. I., Holmes, T. L., Gilmore, T., Hampton, K., …Smith, J. G. W. (2024). Perlecan (HSPG2) promotes structural, contractile, and metabolic development of human cardiomyocytes. Cell Reports, 43(1), Article 113668. https://doi.org/10.1016/j.celrep.2023.113668

Journal Article Type Article
Acceptance Date Dec 22, 2023
Online Publication Date Jan 9, 2024
Publication Date Jan 23, 2024
Deposit Date Mar 8, 2024
Publicly Available Date Mar 12, 2024
Journal Cell Reports
Publisher Cell Press
Peer Reviewed Peer Reviewed
Volume 43
Issue 1
Article Number 113668
DOI https://doi.org/10.1016/j.celrep.2023.113668
Keywords General Biochemistry, Genetics and Molecular Biology
Public URL https://nottingham-repository.worktribe.com/output/30411797
Publisher URL https://www.cell.com/cell-reports/fulltext/S2211-1247(23)01679-0?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2211124723016790%3Fshowall%3Dtrue

Files





You might also like



Downloadable Citations